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Abstract
Abstract
Type 2 diabetes (T2D) is an independent risk factor for sleep breathing disorders. However,
it is unknown whether T2D affects daily somnolence and quality of sleep independently of
the impairment of polysomnographic parameters.
Material and Methods
A case-control study including 413 patients with T2D and 413 non-diabetic subjects, matched
by age, gender, BMI, and waist and neck circumferences. A polysomnography was performed
and daytime sleepiness was evaluated using the Epworth Sleepiness Scale (ESS). In addi-
tion, 135 subjects with T2D and 45 controls matched by the same previous parameters were
also evaluated through the Pittsburgh Sleep Quality Index (PSQI) to calculate sleep quality.
Results
Daytime sleepiness was higher in T2D than in control subjects (p = 0.003), with 23.9% of sub-
jects presenting an excessive daytime sleepiness (ESS>10). Patients with fasting plasma
glucose (FPG13.1 mmol/l) were identified as the group with a higher risk associated with
an ESS>10 (OR 3.9, 95% CI 1.8–7.9, p = 0.0003). A stepwise regression analyses showed
that the presence of T2D, baseline glucose levels and gender but not polysomnographic
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parameters (i.e apnea-hyoapnea index or sleeping time spent with oxigen saturation lower
than 90%) independently predicted the ESS score. In addition, subjects with T2D showed
higher sleep disturbances [PSQI: 7.0 (1.0–18.0) vs. 4 (0.0–12.0), p<0.001].
Conclusion
The presence of T2D and high levels of FPG are independent risk factors for daytime
sleepiness and adversely affect sleep quality. Prospective studies addressed to demon-
strate whether glycemia optimization could improve the sleep quality in T2D patients
seem warranted.
Introduction
The well-known negative impact of sleep breathing disorders on glucose metabolism has
switched to a bidirectional relationship during the last decade, in which type 2 diabetes (T2D)
has appeared to be an independent risk factor for both nocturnal intermittent hypoxia and
sleep fragmentation [1, 2]. In this regard, the sleeping time spent with oxygen saturation lower
than 90% (CT90) is three-fold higher among obese subjects with T2D in comparison with con-
trol subjects. In addition, different patterns of sleep disordered breathing have been described
in this population, mainly characterized by an increase in apneic events [3, 4]. Furthermore,
when metabolic control is improved in patients with T2D it results in a fast and significant
reduction in oxygen desaturation events [5]. However, there is a lack of specific studies aimed
at investigating whether T2D and metabolic control are also linked to changes in quality of
sleep and daytime somnolence.
The problem is of major clinical relevance when we consider that the prevalence of sleep
apnea-hypopnea syndrome (SAHS) in subjects with T2D reaches from 40% to 86%, in compar-
ison to the 2 to 4% of symptomatic SAHS in general population [6–8]. Therefore, a growing
awareness of the importance of screening and identifying sleep breathing disorders in patients
with T2D has emerged in recent years, not only to modify their cardiovascular and metabolic
risk profile but also the day to day consequences [9]. However, formal sleep studies in Sleep
Units are time consuming and not economically viable for testing entire populations.
Sleep questionnaires have been suggested as a good tool to evaluate not only the risk of hav-
ing sleep apnea, but also nocturnal abnormalities and the daily consequences related to sleep
breathing disorders [10].
However, and although T2D has been sporadically related with daytime sleepiness, it is
unknown whether T2D impairs daily somnolence and quality of sleep independently from
polysomnographic parameters such as CT90 and apnea-hypopnea index (AHI) [11–14]. In
order to shed light to this issue we have designed a case-control study addressed to globally
evaluate the deleterious effect of T2D on daily somnolence and sleep quality by means of the
administration of specific questionnaires.
Material and Methods
Ethics statement
Informed written consent was obtained from all participants, and the human ethics committee
of the three participating University Hospitals (Vall d’Hebron, Arnau de Vilanova, and Sego-
via) approved both the study and the consent procedure.
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Main association
The association of T2D with somnolence symptoms and sleep quality through the administra-
tion of specific questionnaires. The degree of glycaemic control was also considered as a covari-
ate with T2D to evaluate the association with related variables.
Design of the study and description of study population
Somnolence symptoms were evaluated in a first case-control study including 413 patients with
T2D and 413 non-diabetic subjects (controls), matched by age, gender, BMI, and waist and
neck circumferences. Sleep quality was assesses in a second case-control study including 45
patients with T2D and 135 non-diabetic subjects (controls), matched by age, gender, BMI, and
waist circumference (but no neck circumference). The STROBE criteria were followed to report
the results [15].
Description of patients being evaluated for daily somnolence
A total of 1093 patients of Caucasian origin attending the outpatient endocrinology clinic of
three university hospitals (Arnau de Vilanova, Vall d’Hebron, and Segovia) were enrolled at
the time of a regular visit between January 2010 and December 2014. The degree of sleepiness
was evaluated using the Epworth Sleepiness Scale (ESS). Data from an overnight sleep study
were available from five hundred and six (62%) of these subjects, more of them obese subjects
also evaluated for bariatric procedures.
Inclusion criteria included: age older than 18 years, known T2D for longer than 5 years,
blood fasting plasma glucose (FPG) and glycated hemoglobin determinations during the pre-
ceding month, the absence of reported nocturnal hypoglycemia or a previous history of severe
hypoglycemia, and the ability to read and understand the correct meaning of the questions.
On this basis, among the 498 patients with T2D who met inclusion criteria, 85 were
excluded because of the following explanations: missing data (n = 43), chronic pulmonary dis-
ease (n = 13) or treatment with continuous positive airway pressure (CPAP) (n = 9), stroke or
heart failure (n = 8), alcohol abuse or the use of sedatives (n = 5), active malignancy (n = 4),
shift workers (n = 2), and clinical manifestations of diabetic autonomic neuropathy (n = 1).
Among non-diabetic subjects, we aimed to select one control for every case and, subsequently,
the control group consisted of 413 subjects individually matched to cases by age (within
3-years range), gender, BMI (within 3.5 kg/m2 range), waist and neck circumferences, and
smoking status. The main clinical characteristics and metabolic data of this population are
shown in Table 1.
Description of patients being evaluated for sleep quality
The Pittsburgh Sleep Quality Index (PSQI) questionnaire, which calculates sleep quality and
disturbances, was also administered to 331 patients attending the same outpatient clinics
between May 2013 and December 2014. Among the 173 patients with T2D who met the same
previous inclusion criteria, 38 were excluded because of the following explanations: missing
data (n = 27), chronic pulmonary disease or CPAP treatment (n = 5), stroke or heart failure
(n = 3), alcohol abuse or the use of sedatives (n = 2), and shift workers (n = 1). We selected one
control for every three cases and, subsequently, the control group consisted of 45 subjects with-
out diabetes matched to cases by age (within 7-years range), gender, BMI (within 4.5 kg/m2
range), and smoking status. No data from an overnight sleep study were available from these
subjects. The main clinical characteristics and metabolic data from this second population are
shown in Table 2.
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In all cases, after obtaining informed consent, participants were asked about demographic
data and medical history. T2D was defined according to the criteria recommended by the
Expert Committee on the Diagnosis and Classification of Diabetes [16].
Specific questionnaires
The ESS was created in 1991, and has become the most common method worldwide to for
evaluating the subjective degree of sleepiness. The questionnaire asks respondents to rate their
likelihood of falling asleep unintentionally in 8 situations of real-life [17, 18]. The score ranged
from 0 (would never doze) to 3 (high chance of dozing), with the higher scores indicate being
more sleepy. Daytime sleepiness is considered high when it’s higher than 10.
The PSQI evaluates subjective sleep quality over the preceding month [19]. It is a 19-item
questionnaire grouped into seven component scores, each weighted equally on a 0–3 scale,
dealing with major aspects of sleep (subjective sleep quality, sleep latency, sleep duration, sleep
efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction). The
seven components are then added up to yield a global PSQI score (range: 0–21), where higher
scores reflects worse subjective sleep quality, and a PSQI global score greater than 5 identifies
poor sleepers.
Table 1. Main clinical characteristics andmetabolic data of participants included in the study evaluating daytime somnolence. AHI: apnea hypop-
nea index.
Type 2 Diabetes Non Type 2 Diabetes Mean difference (95% CI) p value
N 413 413 - -
Women, n (%) 215 (52,0) 215 (52,0) - -
Age (years) 55.9 ± 10.4 55.0 ± 10.0 0.9 (-0,5 to 2.2) 0.712
BMI (kg/m2) 36.8 ± 8.1 36.4 ± 9.0 0.4 (-07 to 1.6) 0.458
Waist circum. (cm) 115.5 ± 16.0 114.8 ± 17.2 0.7 (-1.9 to 3.3) 0.583
Neck circum. (cm) 40.1 ± 5.9 40.8 ± 4.2 -0.7 (-1.7 to 0.3) 0.185
Glucose (mmol/l) 9.1 ± 3.1 5.4 ± 0.6 3.7 (3.3 to 4.0) < 0.001
HbA1c (%) 7.9 ± 1.6 5.7 ± 0.4 2.2 (2.0 to 2.4) < 0.001
HbA1c (mmol/mol) 63.4 ± 17.5 38.9 ± 5.2 24.5 (22.4 to 26.5) <0.001
AHI (events/hour) a 25.7 (1.0 to 128.0) 24.1 (0.0 to 118.2) - 0.060
a Data from an overnight sleep study were only available from 175 patients with type 2 diabetes and 332 controls.
doi:10.1371/journal.pone.0157579.t001
Table 2. Main clinical characteristics andmetabolic data of the subgroup of participants included in the study evaluating risk of sleep apnea sleep
quality.
Type 2 Diabetes Non Type 2 Diabetes Mean difference (95% CI) p value
N 135 45 - -
Women, n (%) 75 (55.5) 25 (55.5) - -
Age (years) 60.9 ± 12.6 59.0 ± 12.0 1.9 (-2.3 to 6.1) 0383
BMI (kg/m2) 30.9 ± 5.3 29.6 ± 7.0 1.4 (-0.6 to 3.3) 0.192
Waist circum. (cm) 105.9 ± 14.5 105.0 ± 14.1 0.8 (-4.6 to 6.4) 0.001
Glucose (mmol/l) 8.1 ± 2.9 5.3 ± 0.7 2.7 (2.2 to 3.3) < 0.001
HbA1c (%) 7.7 ± 1.7 5.7 ± 0.5 2.0 (1.5 to 2.4) < 0.001
HbA1c (mmol/mol) 61.0 ± 18.7 39.1 ± 6.3 21.9 (17.0 to 26.8) <0.001
doi:10.1371/journal.pone.0157579.t002
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Statistical analysis
The normal distribution of the variables was evaluated using the Kolmogorov-Smirnov test.
Data were expressed either as the mean ± SD, percentage or median (total range). For paramet-
ric tests, AHI, and CT90 were logarithmically transformed to achieve a normal distribution.
Comparisons between groups were performed using the Student’s t test or the Mann-Whitney
U test for continuous variables, as well as the χ2 test for categorical variables.
Regression trees were used to specifically assess the relationship and potential interaction of
HbA1c and FPG with ESS, and the minimization of the reduction in the mean squared error
was applied as a statistical criterion. Partitions were defined by the systematic exploration of all
possible thresholds, and using the Gini criterion to select the on with the highest predictive
value. This was performed using a computational intensive algorithm. Therefore, three parti-
tions were defined: (i) HbA1c<6.4% (46.0 mmol/mol); (ii) HbA1c6.4% (45.5 mmol/mol)
and FPG<13.1 mmol/mol; and (iii) HbA1c6.4% (45.5 mmol/mol) and FPG13.1 mmol/l.
The association of each partition with ESS was then assessed with a Kruskal-Wallis test, and
the value of the partition as a predictor of ESS>10 was assessed with a logistic regression
model. In addition, the odds-ratios, 95% confidence intervals, and corresponding p-values
from aWald test were calculated. A Receiver Operating Characteristic (ROC) analysis and sen-
sitivity and specificity analyses were also performed.
Furthermore, to evaluate the relationship between age, BMI, waist and neck circumference
and polysomnographic measurements with ESS the Pearson linear correlation test was per-
formed. Additionally, stepwise multiple linear regression analyses to explore the variables inde-
pendently related to the ESS score were also performed. The independent variables included in
the analyses were: gender, polysomnographic measurements (AHI and CT90), and the either
the presence or absence of T2D or baseline blood glucose levels. All p- values were two-sided,
setting the threshold for significance at p<0.05. Statistical analyses were performed using the
SSPS statistical package (SPSS, Chicago, IL, USA) and the R statistical package [20].
Results
The ESS global score was significantly higher in patients with T2D (7.4±4.5 vs. 6.5±4.3;
p = 0.003), with 23.9% of subjects with T2D presenting an excessive daytime sleepiness (ESS
score>10) (23.9% vs. 16.9%, p = 0.016). When all subjects were evaluated, the ESS global
score was higher in men than in women (7.5±4.3 vs. 6.5±4.5, p = 0.002), and in those with an
HbA1c 7.0% (53.0 mmol/mol) or FPG 7.0 mmol/l in comparison with those with lower
parameters (7.3±4.7 vs. 6.5±4.1, p = 0.031, and 7.4±4.4 vs. 6.6±4.3, p = 0.018, respectively).
The regression tree analysis revealed a partition of patients into three groups significantly
associated to ESS levels (p = 0.005) (Fig 1A). Subjects with HbA1c<6.4% (46.0 mmol/mol)
were identified as the lower risk group for EDS (ESS: 6.2±4.2). Meanwhile, among patients
with higher degrees of HbA1c, those with FPG<13.1 mmol/l showed an intermediate ESS
score (ESS: 7.1±4.4), and those with higher FPG levels were identified as the higher risk group
for EDS (ESS 8.6±4.4) (Fig 1A). When specifically assessing the risk of excessive daytime sleepi-
ness (ESS>10) the intermediate group showed an increased risk with respect to the low group
close to statistical significance (OR = 1.63 and p = 0.053), and the high risk group showed a
clearly significant increase in daytime sleepiness risk (OR = 3.9, 95% CI 1.8–7.9, p = 0.0003)
(Fig 1B and Table 3).
In the univariate analysis, a correlation between daytime sleepiness and polysomnographic
measurements was found (CT90: p = 0.044, r = 0.092; and AHI: p = 0.003, r = 0.130) but
we did not find any correlation between ESS score and FPG (p = 0.269, r = 0.043), HbA1c
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(p = 0.147, r = 0.065), age (p = 0.828, r = 0.008), BMI (p = 0.661, r = -0.015), waist (p = 0.313,
r = 0.041) and neck (p = 0.119, r = 0.082) circumferences.
A stepwise regression analysis showed that the presence of T2D (beta = 0.222, p<0.001)
and gender (beta = 0.112; p = 0.013), but not polysomnographic parameters (log CT90:
beta = 0.057, p = 0.210; log AHI: beta = 0.072, p = 0.118] independently predicted the ESS
score (R2 = 0.057). In addition, when the presence of T2D was replaced by the FPG, this was
the only variable independently associated with ESS score (R2 = 0,012; beta = 0,111, p = 0,028).
On the other hand, the PSQI global score was significantly higher in patients with T2D than in
control subjects [7.0 (1.0–18.0) vs. 4 (0.0–12.0), p<0.001]. Almost 2 out of every 3 patients with
diabetes were classified as poor sleepers (PSQI global score>5: 67.4% vs. 37.7%, p<0.001), and
this subjective sleep quality reduction was associated with higher age (62.5±12.4 vs. 57.0±11.9
years, p = 0.003) and higher FPG (140.6±56.5 vs. 124.5±40.8 mg/dl, p = 0.041), but not with
HbA1c or with anthropometric values. In addition, a PSQI global score> 5 was also associated
with a higher percentage of patients with an ESS score> 10 (25.4 vs. 12.1%, p = 0.024), with a sig-
nificative and positive linear correlation between the PSQI and ESS scores (r = 0.214; p = 0.004).
Discussion
We provide evidence that T2D is associated with impaired scores in different questionnaires
that globally evaluate the risk of having daytime somnolence, and sleep quality.
Fig 1. Association of HbA1c and glycemic levels (FPG) with ESS. (A) Patients classified in three different
groups according to HbA1c and FPG levels: [HbA1c < 6.4% (46.0 mmol/mol)], [HbA1c6.4% (46.0 mmol/
mol) and FPG <13.1 mmol/l] and [HbA1c6.4% (46.0 mmol/mol) and FPG13.1 mmol/l]. Mean ESS levels
and standard deviation are shown. (B) Odds-ratios (OR) with corresponding 95%CI to assess the increased
risk of excessive daily somnolence (defined as ESS>10) in groups [HbA1c6.4% (46.0 mmol/mol) and FPG
<13.1 mmol/l] and [HbA1c6.4% (46.0 mmol/mol) and FPG13.1 mmol/l] with respect to group
[HbA1c < 6.4% (46.0 mmol/mol)].
doi:10.1371/journal.pone.0157579.g001
Table 3. Assessment of the risk of excessive daily somnolence (defined as ESS > 10) in three different
groups based on HbA1c and FPG levels. Baseline category (intercept) refers to patients with low HbA1c
[<6.4% (46.0 mmol/mol)]. OR (95%CI): odds-ratio with corresponding 95% confidence interval; p-value from
aWald test; beta (SE): estimated parameters and standard deviation from a logistic regression model are
shown. ESS: Epworth Sleepiness Scale.
Beta (SE) OR (95% CI) p value
Intercept [HbA1c < 6.4% (46.0 mmol/mol)] -1.76 (0.20) - -
HbA1c 6.4% (46.0 mmol/mol) and FPG <13.1 mmol/l 0.49 (0.25) 1.63 (1.002, 2.72) 0.053
HbA1c 6.4% (46.0 mmol/mol) and FPG 13.1 mmol/l 1.34 (0.37) 3.81 (1.82, 7.91) 0.0003
doi:10.1371/journal.pone.0157579.t003
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Our results show that excessive daytime sleepiness (EDS) is a common feature in T2D and
affects almost one quarter of this population. In a previous work, Bixler et al, in a random sam-
ple of 16,583 men and women, identified being treated for depression as the most important
risk factor for the complaint of EDS, followed by BMI, age, subjective sleep duration, smoking,
sleep apnea, and also T2D [12]. In addition, it has been suggested that subjects with T2D expe-
rience dozing when stopped for a few minutes in traffic while driving, increasing their risk for
traffic accidents [14].
Increasing attention has to be paid to this data for care providers, as EDS has been previ-
ously associated with a general decrease in motivation to participate in activities related to the
management of T2D [13]. There are also studies that have failed to demonstrate an association
between T2D and EDS. Basta el al. reported in a cohort of 1,106 consecutive patients with sleep
apnea that the predictors of EDS were AHI, the lack of regular exercise, and depression, but
not the presence of T2D [11]. However, symptoms consistent with sleep apnea were required
in order to be included in this series, and therefore this is not comparable with the T2D patients
included in our study.
The present study strongly suggests that the presence of T2D is related to EDS indepen-
dently of other classic risk factors such as SAHS. Our results agree with those previously pub-
lished by Dixon et al. [21] in 1,055 consecutive obese subjects waiting for bariatric surgery. In
this study the ESS global score was higher in men, older patients, and those with T2D, whereas
no relationship between daytime somnolence and polysomnography measurements, including
the AHI, were reported. In addition, we observed that EDS was evident in those patients with
higher FPG levels but an independent relationship with HbA1c was not found. These results
suggest a relationship between EDS and immediate or short term glucose fluctuations rather
than with sustained glycemic control.
According to the PSQI, more than half of the patients with T2D were “poor sleepers”.
Recently, poor sleep quality was proved to increase the risk of the development of T2D in a
Chinese adult population during a 5-year follow-up period [22], and the PSQI score has been
positively correlated with inflammatory markers such as IL-6 and ICAM-1 [23]. In addition,
“poor sleep” has been associated with worse diabetes-related quality of life, a greater number of
diabetic complications, and higher levels of depressive symptoms [24]. Similarly, lower sleep
quality was associated with poorer glucose control, after controlling for age, gender, BMI, insu-
lin use, and the presence of complications [25]. Several factors could influence the bad sleep
quality reported by participants with T2D such as pain due to peripheral neuropathy, nocturia,
sleep apnea, and restless leg syndrome, all of them associated with frequent nighttime awaken-
ings contributing to exacerbate sleep disruption [26–28]. In our study sleep quality reduction
was associated with basal hyperglycemia but not with HbA1c, strengthening the potential rela-
tionship between nocturnal hyperglycemia and sleep quality. Moreover, in our study, sleep
quality was associated with daytime sleepiness, thus reinforcing the potential effect of sleep in
the daily functioning of patients with T2D.
Some limitations should be taken into account in evaluating the outcome of our study. First,
this was an observational study and, therefore, we cannot draw a causal link between T2D or
blood glucose levels and either the sleep or the daytime consequences. In this regard, research
addressed to determining whether the short term improving of metabolic control ameliorates
daytime somnolence and sleep quality is warranted. Conversely, the effect of sleep quality on
blood glucose levels should also be examined. Second, as daytime sleepiness often occurs dur-
ing the postprandial status, a potential relationship between EES and postprandial glucose lev-
els could be speculated. Nevertheless, no data about glucose profiles is available from patients
included in this study. Another limiting factor is that sleep characteristics and daytime sleepi-
ness were subjectively assessed, and perhaps a more objective test, i.e. the Multiple Sleep
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Latency Test (MSL-T), could have found a greater percentage of sleepy patients [29, 30]. In this
way, confounding factors like the number of times a subject has to get up for urination or the
number of working day hours have not been included in the analysis of results. However, the
ESS is used worldwide in routine clinical practice as a standard measure in the evaluation of
EDS.
In conclusion, T2D and high levels of FPG are independent risk factors for daytime sleepi-
ness and sleep quality. Prospective studies addressed to demonstrate whether glycemia optimi-
zation could improve the sleep quality in T2D patients seems warranted. In addition, our
findings emphasize the importance of screening new patients for sleep problems, with a referral
to a sleep medicine specialist if appropriate, and suggest sleep hygiene strategies as a part of
diabetes management.
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